Sessions 

Light Breakfast: served until 10:45

Drug Discovery & Development Mon, Mar 18 | 16:00-16:15 | room 131/132 Evariste

Antibodies Mon, Mar 18 | 16:45 - 17:00 | room 131/132 Innovent Biologics

Drug Discovery & Development Mon, Mar 18 | 15:15-15:30 room 131/132 MindRank

Drug Discovery & Development Mon, Mar 18 | 14:45 - 15:00 | room 131/132 SENISCA

https://www.museunacional.cat/en/museum

Light Breakfast: served until 10:45

Tuesday, 19 March 2024 10:15 - 10:30
CNS/Neurology: Neurocentrx Pharma Ltd

Location: Room 133/134

Pioneering biopharma company Neurocentrx have developed an abuse-deterrent, oral-ketamine therapy for Treatment-Resistant Depression(TRD), which has the potential to provide a convenient, cost-effective means to reduce the high medical morbidity, socio-economic burden, and individual patient suffering associated with TRD

Startup spotlight, cardiovascular
Tue, Mar 19 | 15:18 – 15:24 | room 112
Elastrin Therapeutics Inc.

Startup spotlight, Cell & Gene Therapies Tue, Mar 19 | 16:10 – 16:16 | room 112 Scarlet Therapeutics

Startup spotlight, Respiratory Diseases Tue, Mar 19 | 16:20 – 16:26 room 112 TaBriX

The British Consulate in Barcelona invites you to a networking reception at Bio Europe Spring. hosted by the Department for Business and Trade (DBT) Government BioPharma Specialist, Bill Lindsay, and Lead for BioPharma Sector in Spain from the British Consulate in Barcelona, Jessica Griffiths.

This reception will provide an excellent opportunity to gain knowledge about the UK BioPharma ecosystem, DBT government services to support your company in the UK, as well as a unique networking opportunity to meet with the very best UK BioPharma contacts from a variety of companies, universities, research centres and organisations.

Light Breakfast: served until 10:45

Next Generation: StemcellX Limited

Location: Exhibit hall stage

StemcellX was established with thew mission to bring a novel, stem cell-based regenerative treatment for Osteoarthritis (OA). We bring together a strong and experienced team from the UK and Europe to develop fully licensed products for the benefit of the millions of humans & animals suffering from chronic pain, caused by this debilitating disease.

We have strong academic and industry partnerships in the UK, supporting our R&D programmes, including NGOs, Universities and independent professionals. We also have a highly experienced R&D operation and a purpose built, GMP compliant cell production facility in Hungary.

Our first product, developed for dogs, is now entering final regulatory trials. Using our production technologies, we begun to develop a stem cell treatment for human Osteoarthritis and are currently pursuing a preclinical programme. The feasibility and effectiveness of our approach has recently been showcased by our treatment of an OA sufferer, elderly Gorilla in Budapest Zoo, the first ever primate to benefit from such medication. Since her treatment in August 2023, her quality of life has been transformed, demonstrating the safety and life-changing efficacy our stem cell products in one of our closest relatives.

Company Presentations: Exhibit Hall Stage

Wednesday, 20 March 2024 09:50 - 10:00